Menu
Back to Journals » Infection and Drug Resistance » Volume 3
Infection and Drug Resistance
ISSN: 1178-6973
- View all (3543)
- Volume 17, 2024 (149)
- Volume 16, 2023 (705)
- Volume 15, 2022 (735)
- Volume 14, 2021 (553)
- Volume 13, 2020 (470)
- Volume 12, 2019 (399)
- Volume 11, 2018 (262)
- Volume 10, 2017 (60)
- Volume 9, 2016 (34)
- Volume 8, 2015 (39)
- Volume 7, 2014 (38)
- Volume 6, 2013 (25)
- Volume 5, 2012 (20)
- Volume 4, 2011 (23)
- Volume 3, 2010 (16)
- Volume 2, 2009 (5)
- Volume 1, 2008 (10)
Archive: Volume 3, 2010
Current strategies for the prevention and management of central line-associated bloodstream infections
Zhuolin Han, Stephen Y Liang, Jonas Marschall
Infection and Drug Resistance 2010, 3:147-163
Published Date: 23 November 2010
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents
Josep Quer, Maria Buti, Maria Cubero, et al
Infection and Drug Resistance 2010, 3:133-145
Published Date: 23 November 2010
Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis
Martha K Daddario, Jennifer K Hagerman, Michael E Klepser
Infection and Drug Resistance 2010, 3:123-132
Published Date: 28 October 2010
Multidrug and extensively drug-resistant tuberculosis from a general practice perspective
BM Yashodhara, Choo Beng Huat, Lakshmi Nagappa Naik, et al
Infection and Drug Resistance 2010, 3:115-122
Published Date: 22 October 2010
Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
Charlotte Charpentier, Laurence Weiss
Infection and Drug Resistance 2010, 3:103-114
Published Date: 13 October 2010
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
Andres Beiras-Fernandez, Ferdinand Vogt, Ralf Sodian, et al.
Infection and Drug Resistance 2010, 3:95-101
Published Date: 30 August 2010
Acquired resistance of malarial parasites against artemisinin-based drugs: social and economic impacts
Johanna M Porter-Kelley, Joann Cofie, Sophonie Jean, et al
Infection and Drug Resistance 2010, 3:87-94
Published Date: 19 August 2010
Methicillin-resistant Staphylococcus aureus in HIV-infected patients
Alicia I Hidron, Russell Kempker, Abeer Moanna, et al
Infection and Drug Resistance 2010, 3:73-86
Published Date: 6 August 2010
The use of anti-tuberculosis therapy for latent TB infection
Justin T Denholm, Emma S McBryde
Infection and Drug Resistance 2010, 3:63-72
Published Date: 21 July 2010
Long-term epidemiology of bacterial susceptibility profiles in adults suffering from febrile neutropenia with hematologic malignancy after antibiotic change
J Mebis, H Jansens, G Minalu, et al
Infection and Drug Resistance 2010, 3:53-61
Published Date: 28 July 2010
Role of posaconazole in the treatment of oropharyngeal candidiasis
Voichita Ianas, Kathryn R Matthias, Stephen A Klotz
Infection and Drug Resistance 2010, 3:45-51
Published Date: 28 June 2010
Drug resistance in community-acquired respiratory tract infections: role for an emerging antibacterial
Lorenzo Aguilar, María-José Giménez, José Barberán
Infection and Drug Resistance 2010, 3:35-43
Published Date: 18 June 2010
Prevention strategies for antimicrobial resistance: a systematic review of the literature
Whitney P Caron, Shaker A Mousa
Infection and Drug Resistance 2010, 3:25-33
Published Date: 21 May 2010
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
Lisa M Chirch, Roy T Steigbigel
Infection and Drug Resistance 2010, 3:15-23
Published Date: 26 April 2010
Emerging agents to combat complicated and resistant infections: focus on ceftobiprole
César Bustos, Jose L Del Pozo
Infection and Drug Resistance 2010, 3:5-14
Published Date: 22 April 2010
Respiratory failure caused by intrathoracic amoebiasis
Toshinobu Yokoyama, Masashi Hirokawa, Yutaka Imamura, et al
Infection and Drug Resistance 2010, 3:1-4
Published Date: 11 March 2010